ITD 0.00% 14.5¢ itl health group limited

Few points to reflect on. On last year financial result BioMed...

  1. 824 Posts.
    lightbulb Created with Sketch. 202
    Few points to reflect on.

    On last year financial result BioMed contributed 4.5 m in EBITDA. and HCA 2.8 m.

    The "custom pack" portion that sold out of the HCA for 14.4m contributed for 12.3 m in revenue
    whereas the remaining portion with the higher profit margin contributed a 8.9 m in revenue.
    Total profit for the HCA was around 1.7 m . Now assuming a split in profit between the two portions.
    ITL may lose 850k in profit for the gain of 14.4 m deal.

    The 10 m cash positive has a much greater earning boost potential used in the BioMedical entity, compared to the loss of 850k in profits annually in the low-margin "custom pack" division.

    Current M/CAP is 41 m , deduct 10 m cash surplus and EV is 31m . consider FY18 profit around 3 m and
    ITL is sitting on a current PE of 10. ( rough calc.)

    I will not be surprised to see a small DIV payout this year as a reward to management which holds around 45 m shares with W. Mobbs founder/ Ceo n chairman holding 35 m shares.

    ALL IS GOOD, looking forward to this year forward-looking numbers following the recent transaction.
 
watchlist Created with Sketch. Add ITD (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.